G1 Therapeuticslogo.JPG
G1 Therapeutics to Participate Virtually in the H.C. Wainwright 24th Annual Global Investment Conference
September 07, 2022 08:00 ET | G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., Sept. 07, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that Jack Bailey, G1’s Chief Executive...
G1 Therapeuticslogo.JPG
G1 Therapeutics to Host Virtual R&D Day on September 15, 2022
September 06, 2022 07:00 ET | G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., Sept. 06, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company will host a virtual...
G1 Therapeuticslogo.JPG
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 01, 2022 17:22 ET | G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., Sept. 01, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options...
G1 Therapeuticslogo.JPG
G1 Therapeutics Provides Second Quarter 2022 Financial Results and Operational Highlights
August 03, 2022 06:30 ET | G1 Therapeutics
- Achieved $8.7 Million in Net Revenue from Sales of COSELA® (trilaciclib) in the Second Quarter of 2022 and $10.6 Million in Total Revenue - - Completed Patient Enrollment in Pivotal Phase 3 Trial...
G1 Therapeuticslogo.JPG
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 01, 2022 17:15 ET | G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., Aug. 01, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options...
G1 Therapeuticslogo.JPG
G1 Therapeutics to Participate Virtually in the 2022 BTIG Biotechnology Conference and the 2022 Wedbush Pacgrow Healthcare Conference
August 01, 2022 09:00 ET | G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., Aug. 01, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company will participate in two...
G1 Therapeuticslogo.JPG
G1 Therapeutics Announces Addition of Norman E. Sharpless to Board of Directors
July 25, 2022 06:30 ET | G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., July 25, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the appointment of Norman E. “Ned”...
G1 Therapeuticslogo.JPG
G1 Therapeutics to Release Second Quarter 2022 Financial Results and Provide Business Update on August 3, 2022
July 20, 2022 09:00 ET | G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., July 20, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a...
G1 Therapeuticslogo.JPG
COSELA® (Trilaciclib Hydrochloride for Injection) Now Approved in China to Decrease the Incidence of Chemotherapy-Induced Myelosuppression in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
July 13, 2022 10:15 ET | G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., July 13, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the China National Medical Products...
G1 Therapeuticslogo.JPG
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 01, 2022 17:20 ET | G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., July 01, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options...